This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/19/2026
| Characteristic | High-Risk Cytogenetics | Standard-Risk Cytogenetics | ||
|---|---|---|---|---|
| ≥PR to BT (n=64) | <PR to BT (n=41) | ≥PR to BT (n=40) | <PR to BT (n=19) | |
| Median age (range), years | 63.5 (43.0-78.0) | 57.0 (43.0-75.0) | 60.0 (27.0-78.0) | 65.0 (38.0-78.0) |
| ISS stage, n (%) | ||||
| I | 47 (73.4) | 23 (56.1) | 31 (77.5) | 13 (68.4) |
| II | 16 (25.0) | 13 (31.7) | 7 (17.5) | 5 (26.3) |
| III | 1 (1.6) | 5 (12.2) | 2 (5.0) | 1 (5.3) |
| Higher baseline tumor burden, n (%) | 4 (6.3) | 10 (24.4) | 5 (12.5) | 3 (15.8) |
| Prior LOTs, n (%) | ||||
| 1 | 26 (40.6) | 9 (22.0) | 14 (35.0) | 6 (31.6) |
| 2 | 24 (37.5) | 17 (41.5) | 14 (35.0) | 8 (42.1) |
| 3 | 14 (21.9) | 15 (36.6) | 12 (30.0) | 5 (26.3) |
| Triple-class refractory,a | 6 (9.4) | 6 (14.6) | 2 (5.0) | 3 (15.8) |
| Response to BT, n (%) | ||||
| sCR | 1 (1.6) | - | 0 | - |
| CR | 3 (4.7) | - | 1 (2.5) | - |
| VGPR | 17 (26.6) | - | 15 (37.5) | - |
| PR | 43 (67.2) | - | 24 (60.0) | - |
| MR | - | 6 (14.6) | - | 2 (10.5) |
| SD | - | 32 (78.0) | - | 17 (89.5) |
| NE | - | 3 (7.3) | - | 0 |
| Abbreviations: BT, bridging therapy; CD, cluster of differentiation; CR, complete response; ISS, International Staging System; LOT, line of therapy; MR, minimal response; NE, not evaluable; PI, proteasome inhibitor; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response. aPI + immunomodulatory agent + CD38 antibodies. | ||||
| Outcome | High-Risk Cytogenetics | Standard-Risk Cytogenetics | ||
|---|---|---|---|---|
| ≥PR to BT (n=64) | <PR to BT (n=41) | ≥PR to BT (n=40) | <PR to BT (n=19) | |
| Median PFS, months (95% CI) | NE (NE-NE) | 35.2 (15.5-NE) | NE (NE-NE) | NE (28.9-NE) |
| Median OS, months (95% CI) | NE (NE-NE) | NE (NE-NE) | NE (NE-NE) | NE (28.9-NE) |
| 30-month PFS rate, 95% CI | 65.1 (51.4-75.8) | 51.2 (35.1-65.2) | 85.0 (69.6-93.0) | 70.2 (40.9-86.9) |
| 30-month OS rate,95% CI | 87.2 (76.1-93.4) | 75.6 (59.4-86.1) | 92.5 (78.5-97.5) | 76.6 (48.0-90.7) |
| Abbreviations: BT, bridging therapy; CI, confidence interval; NE, not evaluable; OS, overall survival; PFS, progression-free survival; PR, partial response. | ||||
| AEs, n (%) | High-Risk Cytogenetics | Standard-Risk Cytogenetics | ||
|---|---|---|---|---|
| ≥PR to BT (n=64) | <PR to BT (n=41) | ≥PR to BT (n=40) | <PR to BT (n=19) | |
| CRS | 47 (73.4) | 34 (82.9) | 28 (70.0) | 16 (84.2) |
| ICANS | 5 (7.8) | 2 (4.9) | 0 | 1 (5.3) |
| CNP | 7 (10.9) | 4 (9.8) | 2 (5.0) | 2 (10.5) |
| IEC-parkinsonism | 0 | 1 (2.4)b | 0 | 0 |
| Grade 3/4 infections | 28 (43.8) | 20 (48.8) | 12 (30.0) | 5 (26.3) |
| NRM | 7 (10.9) | 6 (14.6) | 2 (5.0) | 4 (21.1) |
| Infectionsa | 4 (6.2) | 5 (12.2) | 0 | 2 (10.5) |
| Abbreviations: AE, adverse event; BT, bridging therapy; CNP, cranial nerve palsy; COVID-19, coronavirus disease 2019; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; IEC, immune effector cell; NRM, nonrelapse mortality; PD, progressive disease; PR, partial response. a≥PR to BT: COVID-19 infection (n=2), cytomegalovirus colitis (n=1), fungal pneumonia (n=1); <PR to BT: COVID-19 infection (n=5), pneumonia (n=1), Pneumocystis jirovecii pneumonia (n=1). bOccurred in a patient with unconfirmed PD at CARVYKTI infusion. | ||||
| Characteristics | ≥25% Tumor Burden Decrease (n=148) | <25% Tumor Burden Decrease (n=28) |
|---|---|---|
| ISS stage, n (%) | ||
| I | 105 (70.9) | 16 (57.1) |
| II | 37 (25.0) | 8 (28.6) |
| III | 6 (4.1) | 4 (14.3) |
| Median years since diagnosis, (range) | 3.4 (0.3-18.1) | 3.2 (0.3-12.1) |
| Presence of soft tissue plasmacytomas, n (%) | 25 (16.9) | 5 (17.9) |
| ≥60% plasma cells,a bone marrow, or aspirate, n (%) | 23 (15.6) | 10 (35.7) |
| Cytogenetic risk,a n (%) | ||
| Standard risk | 50 (34.0) | 9 (32.1) |
| High risk | 88 (59.9) | 17 (60.7) |
| Abbreviations: ISS, International Staging System. aPercentages were based out of n=147 for the ≥25% tumor burden reduction subgroup based on sample availability. | ||

Abbreviations: CI, confidence interval; PFS, progression-free survival.

Abbreviations: Cmax, chimeric antigen receptor-T-cell peak expansion; E:T, effector-to-target ratio; IQR, interquartile range; sBCMA, soluble B-cell maturation antigen.
| Response to Bridging Therapy, n (%) | Number of Patients N=196 |
|---|---|
| ≥VGPR | 42 (21.4) |
| PR | 70 (35.7) |
| Minimal disease/SD | 61 (31.1) |
| PD | 20 (10.2) |
| NE | 3 (1.5) |
| Abbreviations: NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response. | |
| Response with CARVYKTI | ≥VGPR n=42 | PR n=70 | Minimal disease/SD n=61 | PD n=20 |
|---|---|---|---|---|
| 30-month PFS rate, % | 75.9 | 72.9 | 56.5 | 30 |
| 30-month OS rate, % | 85.1 | 91.4 | 74.8 | 40 |
| Abbreviations: OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease; VGPR, very good partial response. | ||||
| AE, n (%) | ≥VGPR n=42 | PR n=70 | MR/SD n=61 | PD n=20 |
|---|---|---|---|---|
| CRSa | 28 (66.7) | 53 (75.7) | 51 (83.6) | 17 (85) |
| ICANS | 2 (4.8) | 3 (4.3) | 3 (4.9) | 7 (35) |
| CNPa | 5 (11.9) | 5 (7.1) | 5 (8.2) | 1 (5) |
| IEC-parkinsonism | 0 | 0 | 1 (1.6)b | 1 (5) |
| Grade 3/4 infectionsa | 17 (40.5) | 25 (35.7) | 25 (41) | 6 (30) |
| Nonrelapse mortalityc | 3 (7.1) | 6 (8.6) | 11 (18) | 6 (30) |
| Fatal infections | 1 (2.4) | 3 (4.3) | 8 (13.1) | 3 (15) |
| Prolonged grade 3/4d | ||||
| Thrombocytopenia | 4 (9.5) | 8 (11.4) | 7 (11.5) | 10 (50) |
| Neutropenia | 1 (2.4) | 11 (15.7) | 6 (9.8) | 2 (10) |
| Anemia | 0 | 1 (1.4) | 1 (1.6) | 3 (15) |
| Abbreviations: AE, adverse event; CNP, cranial nerve palsy; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; IEC, immune effector cell; MR, minimal disease; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response. aAmong 3 patients who were NE for response to bridging therapy, there were 2 CRS cases, 2 grade 3/4 infections, and 1 CNP case. bOccurred in a patient with unconfirmed PD at CARVYKTI infusion. cDeaths not due to PD were considered nonrelapse mortality at any time prior to clinical data cutoff. dDid not recover to grade 2 by day 60 after CARVYKTI. | ||||
| Total (N=97) | |
|---|---|
| Any bridging therapya | 73 (75) |
| Systemic corticosteroids | 63 (65) |
| Dexamethasone | 62 (64) |
| Methylprednisolone | 2 (2) |
| Antineoplastic agents | 62 (64) |
| Other antineoplastic agents | 58 (60) |
| Bortezomib | 26 (27) |
| Carfilzomib | 17 (18) |
| Daratumumab | 15 (16) |
| Cisplatin | 10 (10) |
| Ixazomib | 2 (2) |
| Venetoclax | 1 (1) |
| Alkylating agents | 32 (33) |
| Cyclophosphamide | 22 (23) |
| Melphalan | 10 (10) |
| Bendamustine | 1 (1) |
| Plant alkaloids and other natural products | 12 (12) |
| Etoposide | 12 (12) |
| Cytotoxic antibiotics and related substances | 5 (5) |
| Doxorubicin | 5 (5) |
| Immunosuppressants | 26 (27) |
| Pomalidomide | 21 (22) |
| Lenalidomide | 6 (6) |
| aPatients may have received more than 1 bridging therapy as part of regimen. | |
| Sidana et al15 | Dhakal et al17 | Rana et al18 | Hansen et al19 | |
|---|---|---|---|---|
| Patients, N | 761 | 134 | 135 | 192 |
| Median follow-up | 10.1 months | 6.9 months from the first TALVEY dose | 12 months (IQR, 7-26) | 13 months (range, 3-38) |
| CAR-T received | CARVYKTI | CARVYKTI, ide-cel | CARVYKTI, ide-cel | CARVYKTI |
| Received BT | n=650 | CARVYKTI, n=98; ide-cel, n=21 | CARVYKTI, n=85; ide-cel, n=50 | n=115a |
| BT type | Not reported | TALVEY | Conventional myeloma-directed therapy; TALVEY; high-dose alkylator | Alkylators (38%); PI-based combinations (24%); immunomodulatory drug/CD38 mAb (17%); TALVEY (9%); other (10%) |
| Response to BT | PR (≥50%), 195 (33%) | CR=25 (18.7%) VGPR=29 (21.6%) PR=41 (30.6%) SD=17 (12.7%) PD=22 (16.4%) | CARVYKTI group (n=85): CR=4 VGPR=15 PR=16 SD=27 PD=12 | In 115 patients with BT and measurable disease: ≥CR=69%; Best ORR=92% In 62 patients with decreased disease: ≥CR=73%; Best ORR=95% In 53 patients with stable/increased disease: ≥CR=64%; Best ORR=89% |
| CRS | Not reported | 68% of patients (grade 1/2, n=79; grade 3, n=1; grade 4, n=1) | Ide-cel group: nonresponders: 93%; no BT: 91%; responders: 67% CARVYKTI group: grade ≥2 in nonresponders vs responders: 31% vs 11% | In 115 patients with BT and measurable disease: any grade, 83% (n=96); grade ≥3, 4% (n=5) In 62 patients with decreased disease: any grade, 77% (n=48); grade ≥3, 2% (n=1) In 53 patients with stable/increased disease: any grade, 91% (n=48); grade ≥3, 8% (n=4) |
| ICANS | Not reported | 6% of patients (grade 3, n=1) | Ide-cel group: 33% (n=9; nonresponders only) CARVYKTI group: Not reported | In 115 patients with BT and measurable disease: any grade, 14% (n=16); grade ≥3, 6% (n=7) In 62 patients with decreased disease: any grade, 10% (n=6); grade ≥3, 2% (n=1) In 53 patients with stable/increased disease: any grade, 19% (n=10); grade ≥3, 11% (n=6) |
| Parkinsonism | 22 cases of parkinsonism: 21 (95%) did not respond to BT Response to BT (PD/SD vs PR): Odds ratio, 9.9 (95% CI, 2-180) | No cases of parkinsonism in the entire cohort | CARVYKTI group: all 4 cases of parkinsonism occurred in BT nonresponders | In 115 patients with BT and measurable disease: 3% (n=3) In 62 patients with decreased disease: 2% (n=1) In 53 patients with stable/increased disease: 4% (n=2) |
| NRM | Response to BT (SD/PD vs PR): Odds ratio, 2.41 (95% CI, 1.07-6.19) | NRM rate: 3% in the entire cohort | CARVYKTI group: NRM was nominally higher in BT nonresponders vs responders (13% vs 6%) | NRM: 8% of patients (13/172; infection-related deaths, n=5; other causes, n=8 [including CRS, IEC-EC, parkinsonism, and SPM]) |
| Abbreviations: BT, bridging therapy; CAR-T, chimeric antigen receptor-T-cell therapy; CD, cluster of differentiation; CR, complete response; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome; ide-cel, idecabtagene vicleucel; IEC-EC, immune effector cell-associated enterocolitis; IQR, interquartile range; mAb, monoclonal antibody; NRM, nonrelapse mortality; PD, progressive disease; PI, proteasome inhibitor; PR, partial response; SD, stable disease; SPM, second primary malignancy; VGPR, very good partial response. aAmong patients with available information on disease change. | ||||
Sidana et al (2025)15 reported a multicenter, retrospective study from the US Multiple Myeloma Immunotherapy Consortium evaluating outcomes of 761 patients treated with CARVYKTI with relapsed MM who were treated at 15 centers between May 2022 and December 2024.
Dhakal et al (2025)17 reported a multicenter retrospective study that evaluated safety and efficacy of a short course of TALVEY (0.8 mg/kg SC every other week) as a bridging therapy prior to CARVYKTI or idecabtagene vicleucel (ide-cel) infusion in 134 patients with RRMM.
Rana et al (2025)18 reported, for a median follow-up of 12 months (IQR, 7-26), results from a single-center, retrospective analysis of 135 patients with RRMM who received CAR T-cell therapy (CARVYKTI, n=85; ide-cel, n=50) between May 2021 and March 2025.
Hansen et al (2026)19 published a single-center, retrospective cohort study that evaluated efficacy and safety outcomes according to bridging therapy response, bridging therapy type, and pre-lymphodepletion plasma cell burden (pre-LD PCB) in patients with RRMM treated with CARVYKTI between May 11, 2022 and January 26, 2025.
Additional real-world studies identified assessing the use of bridging therapy for disease control before CARVYKTI use include:
Sidana et al (2025)20
Ailawadhi et al (2025)21
Flores et al (2026)22
Scott et al (2025)23
A literature search of MEDLINE®
| 1 | San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 |
Would you like to clear and leave your conversation? Message history will be lost.